Metabolon is performing the test in its CLIA registered laboratory in Research Triangle Park, NC.

The company has advanced the field of metabolomics by patenting the biochemical biomarker discovery and profiling platform.

It has developed technology to identify and measure the biochemicals in a biological sample through its proprietary global processing method.

Metabolon said through the generation and interpretation of data, this method provides knowledge about disease etiology and drug action, and advances personalized medicine.

Metabolon CEO John Ryals said their application for College of American Pathologists (CAP) accreditation reinforces Metabolon’s commitment to provide quality in their pursuit to fulfill the promise of personalized medicine.